💊 Obat A-Z 🧬 Target 🛠 Alat 📚 Panduan
Semua Obat Kelas Obat Area Terapeutik Efek Samping
Panduan Glosarium Linimasa
Perbandingan Perjalanan Obat Famili Obat
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Abrocitinib

CHEMBL3655081 Phase 4 Disetujui Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
323.4 g/mol
LogP
1.7
Phase
4

An oral medication that works inside immune cells by blocking a signaling enzyme called JAK1, reducing the inflammatory signals that drive itching and skin inflammation in eczema. It is approved for moderate-to-severe atopic dermatitis in adults and adolescents when other treatments have not worked well enough. Patients should avoid live vaccines while taking it and should be aware of a small increased risk of serious infections, blood clots, and cardiovascular events.

Berat Molekul

323,4200 g/mol

LogP

1,70

TPSA

99,40 Ų

Lipinski RO5

Lulus

Area Terapeutik

Psoriasis Atopic Dermatitis

Mekanisme Kerja

Stimulates the adaptive immune system to produce antigen-specific antibodies and memory cells, providing protective immunity against subsequent exposure to the pathogen.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Stimulates the adaptive immune system to produce antigen-specific antibodies and memory cells, providing protective immunity against subsequent exposure to the pathogen.

Struktur 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCCS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1

                

                

                
                

                    
InChI

                    
InChI=1S/C14H21N5O2S/c1-3-6-22(20,21)18-10-7-11(8-10)19(2)14-12-4-5-15-13(12)16-9-17-14/h4-5,9-11,18H,3,6-8H2,1-2H3,(H,15,16,17)/t10-,11+

                

                

                

                    
                    

                        
Molecular Formula

                        
C14H21N5O2S

                    

                    
                    

                        
HBD / HBA

                        
2 / 6

                    

                    
                    

                        
Ikatan yang Dapat Dirotasi

                        
6

                    

                    
                    
                    

                        
Atom Berat

                        
22

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Pertanyaan yang Sering Diajukan

                

                    
                    

                        
                        

                            
An oral medication that works inside immune cells by blocking a signaling enzyme called JAK1, reducing the inflammatory signals that drive itching and skin inflammation in eczema. It is approved for moderate-to-severe atopic dermatitis in adults and adolescents when other treatments have not worked well enough. Patients should avoid live vaccines while taking it and should be aware of a small increased risk of serious infections, blood clots, and cardiovascular events.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Stimulates the adaptive immune system to produce antigen-specific antibodies and memory cells, providing protective immunity against subsequent exposure to the pathogen.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Abrocitinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL3655081.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 78323835.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Penyangkalan Medis

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.